Bioventus Inc. reported a net revenue of $147.7 million for the three months ended June 28, 2025, a decrease of 2.4% from $151.2 million in the same period last year. For the first half of 2025, the company generated $271.5 million in revenue, down from $280.7 million in the prior year. The company achieved a gross profit of $102.1 million for the quarter, resulting in a gross margin of 69.1%, compared to 68.5% in the previous year. Bioventus also reported a net income of $9.3 million for the quarter, a significant turnaround from a net loss of $34.2 million in the same period last year.
The decline in revenue was attributed to a decrease in sales from the Restorative Therapies segment, which fell by 32.2% due to the divestiture of the Advanced Rehabilitation Business. This was partially offset by growth in the Surgical Solutions segment, which saw a 9.5% increase in sales. The company’s selling, general, and administrative expenses decreased by 18.2% to $79.1 million, primarily due to lower shareholder litigation costs and reduced compensation-related expenses following the divestiture.
In terms of strategic developments, Bioventus completed the sale of its Advanced Rehabilitation Business on December 31, 2024, receiving $24.7 million at closing. The proceeds were used to pay down long-term debt, and the company may receive additional earn-out payments based on future sales performance. Additionally, in July 2025, Bioventus received FDA clearances for two new peripheral nerve stimulation products, TalisMann and StimTrial, which are expected to enhance its portfolio in chronic pain management.
Operationally, Bioventus had approximately 950 employees as of June 28, 2025, and reported a slight increase in accounts receivable to $132.4 million from $127.4 million at the end of 2024. The company’s cash and cash equivalents decreased to $32.9 million from $41.6 million at the end of the previous fiscal year, reflecting cash outflows from operating and financing activities. Looking ahead, Bioventus anticipates continued focus on expanding its product offerings and improving operational efficiencies, while navigating the impacts of market conditions and regulatory changes.
About Bioventus Inc.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.